Presentation (CTI)

OBJECTIVES: Atherosclerotic cardiovascular disease (ASCVD) is a leading contributor to the disease burden in China, CV risk factors are highly prevalent in patients with chronic kidney disease (CKD). Systemic inflammation (SI), often defined as C-reactive protein (CRP)/high-sensitivity CRP (hsCRP) ≥ 2 mg/L, is a recognized risk factor for ASCVD and is associated with residual cardiovascular event risk particularly in advanced stages of CKD. This study aims to estimate the prevalence of ASCVD, CKD, and SI, and to assess the baseline characteristics, clinical outcomes (including the risk of major adverse cardiovascular events) and economic burden of SI among patients with ASCVD and CKD in Northern China.
METHODS: A retrospective study was conducted using electronic health records from Tianjin, a metropolis in Northern China. Diagnosis keywords, ICD-10 codes and laboratory tests were used to define eligible patients. Patients with ASCVD during each calendar year from 2021 to 2023 were included to estimate the prevalence within the Tianjin population. Among patients with ASCVD, further analyses were conducted in patients combined with CKD and SI. Patients were classified as SI cohort if any eligible CRP/hsCRP result was ≥ 2 mg/L, and non-SI cohort if no CRP/hsCRP result met this threshold. Descriptive and statistical analyses were conducted.
RESULTS: The prevalence of ASCVD increased from 19.6% in 2021 to 24.3% in 2023, with both genders showing growth. Among males, prevalence rose from 19.4% to 24.0%, and among females, from 19.9% to 24.7%. Further analyses will be conducted to assess the clinical outcomes and economic burden of SI among patients with ASCVD and CKD.
CONCLUSIONS: The prevalence of ASCVD is increasing, highlighting the importance of identifying high-risk patients. Understanding the prevalence and burden of residual cardiovascular risk in real-world settings can enhance ASCVD management, particularly for high-risk patients with advanced CKD.